Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Has Average Price Target of $683.64

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) have received a consensus recommendation of “Moderate Buy” from the twenty-nine brokerages that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $683.64.

TMO has been the topic of several recent analyst reports. TD Cowen boosted their target price on shares of Thermo Fisher Scientific from $760.00 to $810.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Stifel Nicolaus increased their target price on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a report on Monday, October 12th. Sanford C. Bernstein boosted their price target on shares of Thermo Fisher Scientific from $520.00 to $575.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Finally, HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating and upped their price objective for the stock from $660.00 to $690.00 in a research note on Tuesday, September 1st.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. This represents a 7.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 24,546 shares of company stock worth $15,479,192 over the last three months. 0.33% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TMO. Trustmark Bank Trust Department bought a new stake in Thermo Fisher Scientific during the 3rd quarter worth about $242,000. Voya Investment Management LLC raised its position in Thermo Fisher Scientific by 200.3% during the third quarter. Voya Investment Management LLC now owns 773,639 shares of the medical research company’s stock worth $522,246,000 after acquiring an additional 516,007 shares in the last quarter. Bogart Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $116,000. Prasad Wealth Partners LLC bought a new position in Thermo Fisher Scientific during the third quarter worth $433,000. Finally, Public Sector Pension Investment Board grew its stake in Thermo Fisher Scientific by 153.1% in the 3rd quarter. Public Sector Pension Investment Board now owns 153,446 shares of the medical research company’s stock valued at $101,840,000 after buying an additional 92,817 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: A Nov. 9 analysis highlighted accelerating organic growth, demand for bioproduction and capital returns as supports for Thermo Fisher’s outlook. Article: Should You Continue to Hold TMO Stock in Your Portfolio?
• Positive Sentiment: New market forecasts suggest expanding demand in areas relevant to Thermo Fisher, including gene panels (projected to grow from $4 billion in 2025 to $12.6 billion by 2032) and in-vitro toxicology testing (from $14 billion to $27.4 billion). These could create opportunities, though the reports do not estimate TMO’s share of the growth. Article: Gene Panels Global Strategic Business Report 2026 Article: In Vitro Toxicology Testing Global Strategic Business Report
• Neutral Sentiment: Other reports forecast growth in electrophoresis reagents, DNA/genomic profiling kits and nucleic-acid labeling, and list Thermo Fisher among the market participants. These broad industry projections are supportive context, but do not announce a new TMO contract, product or financial outlook. Article: Electrophoresis Reagents Global Strategic Business Report Article: Global DNA and Genomic Profiling Kits Market Report Article: Nucleic Acid Labeling Global Strategic Business Report
• Neutral Sentiment: A fund-letter recap describes an “overlooked AI connection” to Thermo Fisher, but the available report excerpt gives no details or quantified business impact, limiting its value as a near-term catalyst. Article: Thermo Fisher Scientific Is Benefiting From More Than Healthcare Demand
• Negative Sentiment: The Nov. 9 stock analysis also cautioned that macroeconomic risks and competition could weigh on the outlook, tempering the growth and bioproduction positives. Article: Should You Continue to Hold TMO Stock in Your Portfolio?

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $718.90 on Friday. Thermo Fisher Scientific has a 1-year low of $435.27 and a 1-year high of $723.08. The firm has a fifty day simple moving average of $665.03 and a 200-day simple moving average of $555.61. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $266.37 billion, a price-to-earnings ratio of 29.19, a PEG ratio of 2.94 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same period in the prior year, the business earned $5.79 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, sell-side analysts expect that Thermo Fisher Scientific will post 25.27 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.92%.

About Thermo Fisher Scientific

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.